EUCTR2014-004249-29-GB
进行中（未招募）
1 期
An Open Label, Non-Randomised, Phase II study to Determine if Dabigatran and its Metabolites are Detectable in Breast Milk Following Oral Administration to Non-Breastfeeding Mothers - Dabigatran Presence in Breast Milk (DALMATION)
适应症Future use for VTE prophylaxis.Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
相关药物Pradaxa
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Future use for VTE prophylaxis.
- 发起方
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
- 状态
- 进行中（未招募）
- 最后更新
- 8年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Women aged \=18 years
- •Woman has had a vaginal birth (spontaneous or instrumental)
- •Minimum of 48 hours has passed after delivery of the baby/ removal of epidural catheter or spinal anaesthesia
- •Minimum of 24 hours has passed after the decision has been made and documented in the notes to stop breast feeding the baby after starting/trying to start.
- •Hospital inpatient
- •Woman has been offered the opportunity to have a discussion at delivery and in the immediate postnatal period in relation to their feeding choices using the Feeding Your Baby booklet.
- •Decision has been confirmed by the woman to exclusively formula\-feed her baby (including women who have since decided to stop breast\-feeding their baby)
- •Midwife has confirmed the decision with the woman and has documented this in the Feeding Your Baby Booklet held in the medical notes.
- •Normal renal function test – results of the serum creatinine \<90 micro mol/L.
- •Normal liver function tests – results of the serum ALT •Not taking any medication except paracetamol and / or dihydrocodeine. Women who have been given ibuprofen for pain relief after delivery can be included at least 24 hours after the last dose. Women will be advised not to take non\-steroidal anti\-inflammatory drugs (aspirin, ibuprofen, diclofenac, naproxen, indometnacin) for at least 3 days after taking the study treatment)
排除标准
- •Women who are planning to/are breastfeeding
- •Women who are planning to/giving their baby expressed breast milk
- •Women who are unsure of their decision to breast feed or formula feed
- •Women who are unable to provide written informed consent
- •LMWH thromboprophylaxis is indicated
- •Increased risk of bleeding for any reason
- •An increased tendency to bleed (inborn, of unknown cause or due to other medications)
- •Known contra\-indications to dabigatran
- •On\-going treatment with aspirin, NSAIDs or other drugs that affect haemostasis
- •Treatment with oral ketoconazole or itraconazole, medicines to treat fungal infections
结局指标
主要结局
未指定
相似试验
已完成
2 期
Dabigatran Presence in Breast Milk (DALMATION)Topic: Children, Reproductive HealthSubtopic: Children (all Diagnoses), Reproductive Health & Childbirth (all Subtopics)Disease: All Diseases, Reproductive Health & ChildbirthPregnancy and ChildbirthPreventing deep vein thrombosis after childbirthISRCTN87845776ewcastle upon Tyne Hospitals NHS Foundation Trust2
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of ARGX-113 in patients with Mild to Moderate Pemphigus (Vulgaris or Foliaceus)Pemphigus (Vulgaris or Foliaceus)MedDRA version: 20.0Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858MedDRA version: 20.0Level: LLTClassification code 10057069Term: Pemphigus foliaceusSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2017-002333-40-HUargenx BVBA12
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of ARGX-113 in patients with Mild to Moderate Pemphigus Vulgaris or Foliaceus)EUCTR2017-002333-40-DEargenx BVBA22
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of ARGX-113 in patients with Mild to Moderate Pemphigus (Vulgaris or Foliaceus)EUCTR2017-002333-40-ITARGEN-X BVBA22
进行中（未招募）
不适用
Safety and immunogenicity of GSK Biologicals’ (pre-) pandemic influenza vaccine in children aged 6 to 35 months.Immunisation of healthy children aged 6 to 35 months against H5N1 influenza.Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-004734-33-Outside-EU/EEAGlaxoSmithKline Biologicals120